Mirshahidi S - Search Results

1

Combination antiangiogenic therapy and radiation in head and neck cancers.

Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, Mirshahidi S. Hsu HW, et al. Among authors: mirshahidi s. Oral Oncol. 2014 Jan;50(1):19-26. doi: 10.1016/j.oraloncology.2013.10.003. Epub 2013 Oct 23. Oral Oncol. 2014. PMID: 24269532 Review.

2

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Khan S, et al. Among authors: mirshahidi s. PLoS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737. Epub 2012 Oct 16. PLoS One. 2012. PMID: 23091600 Free PMC article.

3

Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.

Hsu HW, Gridley DS, Kim PD, Hu S, de Necochea-Campion R, Ferris RL, Chen CS, Mirshahidi S. Hsu HW, et al. Among authors: mirshahidi s. Oral Oncol. 2013 Jun;49(6):591-7. doi: 10.1016/j.oraloncology.2013.02.009. Epub 2013 Mar 13. Oral Oncol. 2013. PMID: 23490884

4

Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Necochea-Campion Rd, Chen CS, Mirshahidi S, Howard FD, Wall NR. Necochea-Campion Rd, et al. Among authors: mirshahidi s. Cancer Lett. 2013 Oct 10;339(2):167-74. doi: 10.1016/j.canlet.2013.06.007. Epub 2013 Jun 18. Cancer Lett. 2013. PMID: 23791888 Free PMC article. Review.

5

Early diagnostic value of survivin and its alternative splice variants in breast cancer.

Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Khan S, et al. Among authors: mirshahidi s. BMC Cancer. 2014 Mar 12;14:176. doi: 10.1186/1471-2407-14-176. BMC Cancer. 2014. PMID: 24620748 Free PMC article.

6

Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.

Hsu HW, de Necochea-Campion R, Williams V, Duerksen-Hughes PJ, Simental AA Jr, Ferris RL, Chen CS, Mirshahidi S. Hsu HW, et al. Among authors: mirshahidi s. Oral Oncol. 2014 Jul;50(7):662-9. doi: 10.1016/j.oraloncology.2014.03.006. Epub 2014 Apr 13. Oral Oncol. 2014. PMID: 24735547

7

Down-regulation of LXR/RXR activation and negative acute phase response pathways in colon adenocarcinoma revealed by proteomics and bioinformatics analysis.

Tang H, Mirshahidi S, Senthil M, Kazanjian K, Chen CS, Zhang K. Tang H, et al. Among authors: mirshahidi s. Cancer Biomark. 2014;14(5):313-24. doi: 10.3233/CBM-140409. Cancer Biomark. 2014. PMID: 25171473

8

AML sensitivity to YM155 is modulated through AKT and Mcl-1.

de Necochea-Campion R, Diaz Osterman CJ, Hsu HW, Fan J, Mirshahidi S, Wall NR, Chen CS. de Necochea-Campion R, et al. Among authors: mirshahidi s. Cancer Lett. 2015 Sep 28;366(1):44-51. doi: 10.1016/j.canlet.2015.05.034. Epub 2015 Jun 25. Cancer Lett. 2015. PMID: 26118775 Free PMC article.

9

Proteomic Profiling of Serum-Derived Exosomes from Ethnically Diverse Prostate Cancer Patients.

Turay D, Khan S, Diaz Osterman CJ, Curtis MP, Khaira B, Neidigh JW, Mirshahidi S, Casiano CA, Wall NR. Turay D, et al. Among authors: mirshahidi s. Cancer Invest. 2016;34(1):1-11. doi: 10.3109/07357907.2015.1081921. Epub 2015 Nov 4. Cancer Invest. 2016. PMID: 26536157 Free PMC article.

10

Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.

Shouse G, de Necochea-Campion R, Mirshahidi S, Liu X, Chen CS. Shouse G, et al. Among authors: mirshahidi s. Oncotarget. 2016 Sep 20;7(38):61081-61092. doi: 10.18632/oncotarget.11209. Oncotarget. 2016. PMID: 27531894 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page